Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML

Pharmacologic inhibition of epigenetic enzymes can have therapeutic benefit against hematologic malignancies. In addition to affecting tumor cell growth and proliferation, these epigenetic agents may induce antitumor immunity. Here, we discovered a novel immunoregulatory mechanism through inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmon, Jessica M., Todorovski, Izabela, Stanley, Kym L., Bruedigam, Claudia, Kearney, Conor J., Martelotto, Luciano G., Rossello, Fernando, Semple, Timothy, Arnau, Gisela Mir, Zethoven, Magnus, Bots, Michael, Bjelosevic, Stefan, Cluse, Leonie A., Fraser, Peter J., Litalien, Veronique, Vidacs, Eva, McArthur, Kate, Matthews, Antony Y., Gressier, Elise, de Weerd, Nicole A., Lichte, Jens, Kelly, Madison J., Hogg, Simon J., Hertzog, Paul J., Kats, Lev M., Vervoort, Stephin J., De Carvalho, Daniel D., Scheu, Stefanie, Bedoui, Sammy, Kile, Benjamin T., Lane, Steven W., Perkins, Andrew C., Wei, Andrew H., Dominguez, Pilar M., Johnstone, Ricky W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355625/
https://www.ncbi.nlm.nih.gov/pubmed/35311997
http://dx.doi.org/10.1158/2159-8290.CD-20-1145

Ejemplares similares

Ejemplares similares